Circulation OCTOBER 12, 1999

Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non–Q-Wave Myocardial Infarction: Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B Trial

Elliott M. Antman, Carolyn H. McCabe, Enrique P. Gurfinkel, et al. for the TIMI 11B Investigators

Bottom Line

The TIMI 11B trial demonstrated that in patients with unstable angina or non-Q-wave myocardial infarction, a strategy of acute and continued subcutaneous enoxaparin was superior to intravenous unfractionated heparin in reducing the composite rate of death, non-fatal myocardial infarction, or urgent revascularization.

Key Findings

1. Enoxaparin significantly reduced the composite endpoint of death, myocardial infarction, or urgent revascularization through day 43 compared to unfractionated heparin (17.3% vs. 19.7%; odds ratio 0.85; 95% CI 0.72 to 1.00; P=0.048).

2. The treatment benefit appeared early, with a 24% relative risk reduction in the primary endpoint observed within the first 48 hours (7.3% for unfractionated heparin vs. 5.5% for enoxaparin; P=0.026).

3. There was no significant increase in the rate of major hemorrhage during the acute phase of treatment between the enoxaparin and unfractionated heparin groups, although an increased risk of major hemorrhage was noted in the extended outpatient phase (2.9% vs. 1.5%; P=0.021).

4. The benefit of enoxaparin was sustained throughout the 43-day follow-up period without evidence of a 'rebound' effect after the cessation of therapy.

Study Design

Design

RCT

Double-Blind

Sample

3,910

Patients

Duration

43 days

Median

Setting

Multicenter, 10 countries

Population Patients with unstable angina or non-Q-wave myocardial infarction characterized by ischemic discomfort at rest within 24 hours of enrollment, accompanied by ST-segment deviation or elevated cardiac markers.

Intervention Acute intravenous enoxaparin (30 mg bolus) followed by weight-adjusted subcutaneous enoxaparin (1.0 mg/kg) every 12 hours during the acute phase, and continued subcutaneous fixed-dose enoxaparin during the outpatient phase.

Comparator Intravenous unfractionated heparin (70 U/kg bolus followed by titration to an aPTT of 1.5 to 2.5 times control) for the acute phase, followed by subcutaneous placebo injections during the outpatient phase.

Outcome Composite of all-cause mortality, non-fatal myocardial infarction, or severe recurrent ischemia requiring urgent revascularization through day 43.

Study Limitations

• The study was designed to compare an extended treatment strategy (acute plus outpatient); however, results indicated no incremental benefit from continuing enoxaparin into the outpatient phase beyond the initial hospitalization, while safety concerns regarding major hemorrhage arose during this period.

• The trial specifically excluded patients scheduled for urgent revascularization within 24 hours of enrollment, which may limit the generalizability of these findings to populations managed with an early invasive strategy.

• The trial was not individually powered to detect differences in hard clinical endpoints like all-cause mortality alone, necessitating caution in interpretation of secondary components.

Clinical Significance

The results of TIMI 11B established enoxaparin as an effective, convenient alternative to unfractionated heparin for the acute management of patients with non-ST elevation acute coronary syndromes, offering a simplified administration regimen that does not require laboratory monitoring of anticoagulation intensity.

Historical Context

During the late 1990s, unfractionated heparin was the standard intravenous antithrombin therapy for acute coronary syndromes, despite limitations such as non-specific binding and the need for frequent aPTT monitoring. TIMI 11B, alongside the concurrent ESSENCE trial, provided critical evidence for the efficacy and safety of low-molecular-weight heparins, shifting clinical practice toward the adoption of enoxaparin for non-ST elevation ACS.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What is the primary pharmacological mechanism that distinguishes low-molecular-weight heparins (LMWH) like enoxaparin from unfractionated heparin (UFH) in the treatment of Acute Coronary Syndromes?

Key Response

LMWH has a much higher ratio of anti-Factor Xa to anti-Factor IIa (thrombin) activity compared to UFH (approx 3.8:1 for enoxaparin). Additionally, LMWH binds less to plasma proteins and endothelial cells, resulting in more predictable pharmacokinetics, a longer half-life, and a reduced need for laboratory monitoring (aPTT).

Resident

In the TIMI 11B trial, a significant benefit was seen with enoxaparin over UFH. However, what is the clinical risk associated with 'switching' or 'crossing over' between these two anticoagulants if a patient is moved from a conservative strategy to an urgent invasive strategy (PCI)?

Key Response

Subsequent analyses and trials (like SYNERGY) revealed that crossing over from LMWH to UFH (or vice versa) during the same hospital stay significantly increases the risk of major bleeding. Therefore, residents must stick to one anticoagulant strategy; if a patient on enoxaparin requires PCI, they should receive additional enoxaparin doses if needed rather than switching to UFH.

Fellow

The TIMI 11B trial included a 'chronic phase' of outpatient enoxaparin. How did the results of the chronic phase impact modern management compared to the acute phase findings, and what does this imply about the duration of anticoagulation in NSTE-ACS?

Key Response

While the acute phase showed a significant reduction in events, the chronic phase (outpatient enoxaparin for 43 days) did not provide additional ischemic benefit but did significantly increase major bleeding. This led to the current standard of care where anticoagulation is discontinued immediately after successful revascularization or at the time of hospital discharge.

Attending

TIMI 11B was conducted in an era before the routine use of potent P2Y12 inhibitors like ticagrelor and the widespread use of the radial approach for PCI. How does the 'ischemic-to-bleeding' benefit ratio of enoxaparin change in the context of these modern advancements?

Key Response

Modern therapy (potent DAPT and radial access) significantly reduces both ischemic and bleeding events. This narrows the absolute risk reduction provided by enoxaparin over UFH. While enoxaparin remains a Class I recommendation, the 'anticoagulation floor' is higher today, making the avoidance of crossover and the minimize-duration strategy even more critical to maintain the net clinical benefit.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

TIMI 11B utilized a composite primary endpoint of death, non-fatal MI, and urgent revascularization. Evaluate the limitations of using 'urgent revascularization' as a component in a trial comparing a drug with mandatory lab monitoring (UFH) to one without (Enoxaparin).

Key Response

Urgent revascularization is a 'soft' endpoint because it is partially determined by clinician judgment. Since UFH requires aPTT monitoring and enoxaparin does not, the trial is difficult to truly blind. If clinicians suspected a patient was on UFH (due to aPTT results), it could subconsciously influence their threshold for ordering urgent catheterization, potentially introducing a detection bias that favors the LMWH group.

Journal Editor

If you were reviewing the TIMI 11B manuscript today, how would you evaluate the external validity of the findings given the trial's specific exclusion of patients with high serum creatinine (men >2.0 mg/dL)?

Key Response

Enoxaparin is primarily cleared renally and bioaccumulates in patients with chronic kidney disease (CKD), increasing bleeding risk. Since ACS patients often have co-morbid CKD, excluding this population limits the generalizability of the 'superiority' claim. A tough reviewer would demand a discussion on dose-adjustment or the preference for UFH in the renal failure population, which remains a standard practice today.

Guideline Committee

Based on the evidence from TIMI 11B and ESSENCE, why do current AHA/ACC and ESC guidelines recommend enoxaparin as Class I (Level A), yet explicitly recommend against the prolonged outpatient anticoagulation strategy used in this trial?

Key Response

The guidelines reflect the 'acute benefit' seen in the first 8 days of TIMI 11B. However, the 43-day 'chronic phase' showed a 1.5% major bleeding rate for enoxaparin vs 1.0% for placebo (p=0.02) without further divergence in the death/MI curves. Current guidelines (e.g., 2014 AHA/ACC NSTE-ACS) therefore state anticoagulation should be limited to the duration of hospitalization or until PCI is performed.

Clinical Landscape

Noteworthy Related Trials

1997

ESSENCE Trial

n = 3,171 · NEJM

Tested

Enoxaparin

Population

Unstable angina or non-Q-wave myocardial infarction

Comparator

Unfractionated heparin

Endpoint

Composite of death, myocardial infarction, or recurrent angina

Key result: Enoxaparin was superior to unfractionated heparin in reducing the composite endpoint of death, myocardial infarction, or recurrent angina at 30 days.

1999

FRISC II Trial

n = 2,457 · Lancet

Tested

Dalteparin and early invasive strategy

Population

Unstable coronary artery disease

Comparator

Placebo or conservative strategy

Endpoint

Death or myocardial infarction at 6 months

Key result: An early invasive strategy significantly reduced the rate of death and myocardial infarction compared to a non-invasive approach.

2004

SYNERGY Trial

n = 10,027 · JAMA

Tested

Enoxaparin

Population

High-risk non-ST-segment elevation acute coronary syndromes

Comparator

Unfractionated heparin

Endpoint

All-cause death or nonfatal myocardial infarction

Key result: Enoxaparin showed noninferiority to unfractionated heparin for the primary endpoint, though it was associated with slightly higher rates of major bleeding.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis